Contact Us | 1-800-343-7475

Click the HTML icon in the toolbar above to adjust vertical this spacer.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.


Webinar: 3rd Bio-Techne Targeted Protein Degradation Symposium


July 12, 2022 @ 3 - 6pm BST / 7-10am PT / 10am -1pm ET

This free half-day symposium covers some of the hottest science from the exciting field of TPD and includes talks on anti-viral PROTACs, a clinical candidate Degrader of BRD9, the BromoTag® degradation platform, degraders targeting the CBP/p300 lysine acetyltransferases, new cereblon-recruiting warheads for PROTAC® design and the first public presentation of the new CoraFluor TR-FRET probes for TPD assays.

Speakers


headshot_hannah_maple.png
Welcome and Introduction
Dr. Hannah Maple
Innovation Manager, Bio-Techne



headshot_priscilla_yang.png
Targeted Protein Degradation as an Antiviral Strategy
Prof. Priscilla Yang
Professor, Stanford University
headshot_chris_ott.png
Strategies to Chemically Modulate Enhancers: Degraders of the CBP/p300 Lysine Acetyltransferases
Dr. Christopher Ott
Assistant Professor and Director, MGH
Center for Molecular Therapeutics, Harvard Medical School
headshot_adam_bond.pngheadshot_conner_craigon.png


Development of BromoTAG: A New Ligand Inducible Degron System
Adam Bond
PhD candidate, Centre for Targeted Protein Degradation - University of Dundee
Dr. Conner Craigon
PDRA, Ciulli Lab, Centre for Targeted Protein Degradation - University of Dundee

headshot_ralph_mazitschek.png
Just Wait for It – CoraFluor-Enabled TR-FRET Assay Strategies for Facile PROTAC Profiling
Dr. Ralph Mazitschek
Assistant Professor, Harvard Medical School
headshot_zoran_rankovic.png
Here is Why We Use Phenyl Glutarimide (PG) as an Alternative Cereblon-Directing Warhead for PROTACs
Dr. Zoran Rankovic
Director, CBT Chemistry Centers, St. Jude Children’s Research Hospital

headshot_kate_jackson.png
The Discovery and Characterization of CFT8634: A Potent and Selective Degrader of BRD9 for the Treatment of SMARCB1-Perturbed Cancers
Dr. Kate Jackson
Senior Director of Chemistry, C4 Therapeutics
headshot_joel_CB.png
Closing Remarks
Dr. Joel Cresser-Brown
Senior Product Specialist, Bio-Techne


BromoTag® is a registered trademark of University of Dundee, and is used under license.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Targeted Protein Degradation Symposium

Click the HTML icon in the toolbar above to adjust vertical this spacer.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.